Evaluation Questions

1. A 65-year-old woman with relapsed/refractory multiple myeloma (RRMM) has received 4 prior lines of therapy, including an anti-CD38 monoclonal antibody, lenalidomide, pomalidomide, and carfilzomib. She continues to have disease progression, and you are working with your team to determine the best next line of therapy for her. Based on current evidence, which of the following therapies would likely provide the best efficacy in this patient?

2. BM is a 72-year-old woman who received her third dose of talquetamab 24 hours ago. Upon review of her medical chart on rounds, you notice she has a fever peaking at 40.5 °C. After thorough assessment, the team diagnosis this as grade 1 cytokine release syndrome (CRS). Given the patient's clinical picture and based on standard guidelines, as the pharmacist on the medical team, which of the following is the most appropriate treatment recommendation for this patient's fever?

3. AL is a 62-year-old woman with RRMM who recently received idecabtagene vicleucel 7 days ago. The nursing staff reports that the patient often appears disoriented and fatigued. However, when directly addressed, she becomes alert. When questioned, she is unable to identify the current year or the hospital she is in. Given these clinical findings, she is diagnosed with grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS). Based on the National Comprehensive Cancer Network (NCCN) guidelines, which of the following is the most appropriate treatment for this patient's condition?

4. Which drug targets B-cell maturation antigen (BCMA) and has shown efficacy as a single agent in multiple myeloma?

5. You are creating a clinical practice guideline to operationalize the outpatient administration of bispecific antibodies. Which of the following statements should be placed in your guidelines?